A recent study published in the medical journal Vaccine, co-authored by New Zealand statistician Professor Michael Plank claims COVID ‘vaccines’ significantly mitigated the impact of the Covid-19 pandemic during the Omicron phase.
The study says the mRNA gene therapy marketed to the public as a COVID ‘vaccine’ prevented between 4,000 and 12,000 deaths and reduced hospitalisations by 34,000 to 56,000 in New Zealand over an 18-month period starting January 2022.
According to the paper, New Zealand’s elimination strategy allowed for widespread vaccination before exposure to the virus, contributing to ‘one of the world’s lowest pandemic mortality rates.’
The study highlighted disparities in vaccination rates between Māori and Pākehā populations, noting that equalizing Māori vaccination rates could have prevented up to a quarter of the nearly 300 Māori deaths recorded.
The research received partial funding from the New Zealand Department of the Prime Minister and Cabinet and the Ministry of Health.
US study says COVID jabs killed more people than they saved
Meanwhile a non-state funded peer-reviewed US study in the Cureaus journal has raised significant concerns about the efficacy and safety of mRNA COVID-19 vaccines.
The research scrutinized initial phase 3 trial reports and other studies, finding the vaccines’ effectiveness to be substantially lower than the companies’ claims. The study argues that the vaccines, under conservative assumptions, caused nearly 14 times more deaths than they saved, prompting the researchers to call for a global halt on their use and their removal from childhood immunisation schedules.
Children, who face a very low risk from COVID-19 but a noted risk of permanent heart damage from the vaccines, are highlighted as a group for whom vaccination is particularly unethical.
The study critiques the trial reports for focusing on relative risk reduction while neglecting absolute risk reduction, which provides a more meaningful measure of clinical utility. According to the study, the absolute risk reduction offered by the vaccines is minimal, necessitating the vaccination of a large number of individuals to prevent a single case of COVID-19.
The authors also point out significant safety concerns, noting a higher incidence of serious adverse events among vaccine recipients than initially reported by the FDA. The study attributes numerous cardiovascular, neurological, and other health issues to the vaccines, suggesting a need for more rigorous assessment consistent with scientific standards for vaccine safety. Furthermore, the study comments on the mismatch between the vaccines evaluated in trials and those administered globally, raising questions about the safety and efficacy of the vaccination campaign.
The authors urged a reevaluation of the use and regulatory approval of mRNA gene therapy ‘vaccines’.
Image credit: Mufid Majnun